Key result
The optimal antiplatelet strategy (aspirin versus clopidogrel, or monotherapy versus dual antiplatelet therapy) for secondary prevention in peripheral artery disease remains unclear.
Why the study?
Does a specific antiplatelet strategy (aspirin vs clopidogrel or monotherapy vs DAPT) improve outcomes in patients with peripheral artery disease?
Does a specific antiplatelet strategy (aspirin vs clopidogrel or monotherapy vs DAPT) improve outcomes in patients with peripheral artery disease?
This review highlights the uncertainty regarding the optimal antiplatelet strategy for secondary prevention in patients with peripheral artery disease.
Uncertainty in antiplatelet choice for PAD cautions against uniform recommendations; leaves open the need for dedicated RCTs.
eripheral artery disease (PAD) was identified by the Institute of Medicine as one of the top 100 priorities for comparative effectiveness research because of the large population of patients affected with significant morbidity and mortality, the multiple potential treatment options, and the high costs of care to the health care system. Secondary prevention includes the use of antiplatelet agents and the management of other risk factors, such as tobacco use, diabetes mellitus, hyperlipidemia, and hypertension. It is not clear which antiplatelet strategy (aspirin versus clopidogrel or monotherapy versus dual antiplatelet therapy [DAPT]) is of most benefit. Furthermore, the role of these agents in patients with asymptomatic PAD is also unclear.
No takes yet. Share an insight, caveat, or question.
Schmit et al. (2014) conducted a review in Peripheral artery disease. Antiplatelet agents vs. Alternative antiplatelet strategies was evaluated. The optimal antiplatelet strategy (aspirin versus clopidogrel, or monotherapy versus dual antiplatelet therapy) for secondary prevention in peripheral artery disease remains unclear.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: